Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012

AIDS Research and Human Retroviruses
Susan H EshlemanJ Brooks Jackson

Abstract

We compared nevirapine (NVP) resistance (NVPR) mutations in maternal plasma 7 days vs. 6-8 weeks after single-dose NVP prophylaxis. In the HIVNET 012 trial, Ugandan women received a single dose of NVP in labor for prevention of HIV-1 mother-to-child transmission. NVPR mutations were detected in 70 (25%) of 279 women 6-8 weeks after NVP. Samples collected 7 days after NVP were analyzed from a subset of those 279 women. Genotyping was performed with the ViroSeq HIV-1 Genotyping System. NVPR was analyzed using paired samples from 7 days and 6-8 weeks after NVP. Sixty-five women had genotyping results obtained for samples collected at both 7 days and 6-8 weeks post-NVP. Twenty-one (32%) of those women had NVPR mutations detected in one or both samples. This included three women with NVPR at 7 days only, seven with NVPR at 6-8 weeks only, and 11 with NVPR at both time points. Eight women had >1 NVPR mutation detected 7 days after NVP. Y181C was the most common NVPR mutation detected at 7 days, whereas K103N was the most common NVPR mutation detected at 6-8 weeks. We conclude that NVPR may be detected in women as early as 7 days after single-dose NVP. Complex patterns of NVPR are detected in some women. The Y181C NVPR mutation often ...Continue Reading

References

Mar 18, 2000·Antimicrobial Agents and Chemotherapy·C J PetropoulosJ M Whitcomb
Jan 15, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Susan H EshlemanJ Brooks Jackson

❮ Previous
Next ❯

Citations

Jul 12, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R ColebundersM Sande
Jun 30, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Chantelle Bennetto-HoodEdward P Acosta
Apr 10, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Gonzague JourdainUNKNOWN Program for HIV Prevention and Treatment (PHPT) Study Group
Jun 10, 2005·AIDS Research and Human Retroviruses·Dana JonesSusan H Eshleman
Jan 25, 2005·AIDS Research and Human Retroviruses·Susan H EshlemanSrikanth Tripathy
Mar 16, 2011·Antimicrobial Agents and Chemotherapy·Kimberly L ArmstrongM Essex
Dec 14, 2006·Clinical Drug Investigation·Carlo GiaquintoAnita De Rossi
Nov 26, 2005·Expert Review of Anti-infective Therapy·James McIntyre
Mar 9, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Claire Thorne, Marie-Louise Newell
Jun 7, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·D Heather Watts
Aug 17, 2005·BJOG : an International Journal of Obstetrics and Gynaecology·James McIntyre
Dec 27, 2005·The Lancet Infectious Diseases·Robert ColebundersHarriet Mayanja-Kizza
Mar 22, 2005·Best Practice & Research. Clinical Obstetrics & Gynaecology·J Moodley, D Moodley
Aug 27, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Susan H EshlemanJ Brooks Jackson
Dec 2, 2009·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Philippa M MusokeMary Glenn Fowler
Jul 2, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·David J BackJohn G Gerber
Dec 24, 2005·Current Opinion in Infectious Diseases·James McIntyre
Sep 6, 2019·JCI Insight·Valerie F BoltzJohn W Mellors

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.